What is the NCCN recommended primary induction therapy for patients with multiple myeloma (MM) who are candidates for transplantation?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

For primary induction therapy in patients with MM who are candidates for transplantation, NCCN guidelines recommend the following combinations as preferred regimens [2] :

  • Bortezomib/lenalidomide/dexamethasone (category 1)
  • Bortezomib/cyclophosphamide/dexamethasone  - Preferred initial treatment in patients with acute kidney injury (consider switching to bortezomib/lenalidomide/dexamethasone after kidney function improves) or without access to lenalidomide

Other recommended regimens are as follows:

  • Carfilzomib/lenalidomide/dexamethasone
  • Daratumumab/lenalidomide/bortezomib/dexamethasone
  • Ixazomib/lenalidomide/dexamethasone (category 2B)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!